The role of Prostaglandin E in the tetralogy of fallot to

RUHS, Jaipur, M.Sc Nursing Entrance Exam-2022

Child Health Nursing (Pediatrics)

Medium

Appeared in: RUHS, Jaipur, M.Sc Nursing Entrance Exam-2022

Explanation

Prostaglandin E1 (PGE1) is a potent vasodilator that relaxes the smooth muscle of the ductus arteriosus.
In severe Tetralogy of Fallot (a ductal-dependent lesion), the right ventricular outflow tract is severely obstructed, limiting blood flow to the lungs.
By dilating and maintaining the patency of the ductus arteriosus, PGE1 creates a shunt for blood to flow from the aorta to the pulmonary artery.
This bypass increases pulmonary blood flow, improves oxygen saturation (SpO2), and stabilizes the neonate until surgical correction is possible.

Option A: The fundamental problem in severe TOF is dangerously low pulmonary blood flow. The goal of intervention is to increase, not minimize, this flow to improve oxygenation.
Option C: Constricting the ductus arteriosus in a ductal-dependent condition like severe TOF would be catastrophic, as it would cut off the primary source of pulmonary blood flow, leading to profound hypoxia and circulatory collapse.
Option D: The critical life-threatening issue in severe TOF is hypoxemia due to inadequate blood flow to the lungs. While systemic circulation via the aorta is vital, the specific purpose of PGE1 in this context is to augment pulmonary, not aortic, blood flow.

Clinical Relevance

Nursing practice connection: This is primarily an exam-oriented knowledge point with limited direct bedside application, so retain Pharmacological management of ductal-dependent congenital heart disease (Tetralogy of Fallot) as background academic context rather than a clinical decision trigger.
Nurses are responsible for the continuous intravenous (IV) infusion of PGE1, which requires meticulous management of the infusion pump and IV site to prevent interruption.
Key nursing monitoring includes assessing for therapeutic effects (rising oxygen saturation, improved color) and common adverse effects such as apnea, fever, flushing, and hypotension.
Maintaining patent IV access is a critical patient safety issue. Any interruption in PGE1 infusion can cause the ductus to constrict rapidly, leading to life-threatening hypoxia.

How to Approach the Question

First, identify the core concepts in the question: the drug (Prostaglandin E) and the condition (Tetralogy of Fallot).
Recall the primary pathophysiological problem in severe TOF: obstruction of blood flow from the right ventricle to the lungs, causing cyanosis.
Remember that in a newborn, the ductus arteriosus is a potential 'back door' for blood to get to the lungs from the aorta.
Consider the drug class. Prostaglandins are known to be involved in keeping the ductus arteriosus open during fetal life. Therefore, administering Prostaglandin E would logically be intended to mimic this effect.
Evaluate the options: 'Dilating' the ductus arteriosus directly addresses the need for an alternative route for pulmonary blood flow. The other options either worsen the problem (constrict, minimize flow) or address a non-critical issue (aortic flow).

Concept Tested & Keywords

Concept Tested: Pharmacological management of ductal-dependent congenital heart disease (Tetralogy of Fallot).
Stem keywords: Prostaglandin E, tetralogy of fallot
Lead-in keywords: role of

QrpFkBGskdBDP9YgL5i-9z

E6 Pharmacology Katzung 16e p. 529-531

E6 Pathology- ROBBINS & COTRAN PATHOLOGIC BASIS OF DISEASE 10TH Ed p. 541-543

E6 Nelson Textbook of Pediatrics(2024) — Volume 2 p. 592-594